Bristol-Myers Squibb provides regulatory update in first-line lung cancer
Bristol-Myers Squibb announced it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of data available at this time. January 19, 2017